Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR23036900

—

b7faa8ba-72cc-55bb-b3e5-be3353d5ab36

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ESTROGEN_RESPONSE_EARLY+0.330
  • WNT_BETA_CATENIN_SIGNALING+0.320
  • HYPOXIA+0.310
  • TGF_BETA_SIGNALING+0.300
  • MITOTIC_SPINDLE+0.270
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190
  • APOPTOSIS+0.180
  • FATTY_ACID_METABOLISM+0.180
  • P53_PATHWAY+0.170
  • ADIPOGENESIS+0.160

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.400
  • ALLOGRAFT_REJECTION-0.350
  • INTERFERON_GAMMA_RESPONSE-0.320
  • PANCREAS_BETA_CELLS-0.270
  • OXIDATIVE_PHOSPHORYLATION-0.260
  • IL6_JAK_STAT3_SIGNALING-0.200
  • UNFOLDED_PROTEIN_RESPONSE-0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
  • DNA_REPAIR-0.180
  • INFLAMMATORY_RESPONSE-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR23036901
head-neck@1
——0.758
2TCGA-A2-A0CU-01A-12R-A034-07
breast-umap@18
—B0.659
3SRR23036899
head-neck@1
——0.646
4DRR168554
bladder-landscape@3
——0.632
5TCGA-E2-A15E-01A-11R-A12D-07
breast-umap@18
—A0.631
6MNG1104
mng-umap@100
——0.628
7TCGA-56-8308-01A-11R-2296-07
lung-landscapes@6
—cohortSQ20.623
8MNG127
mng-umap@100
——0.623
9SRR1313124
breast-umap@18
—B0.615
10MNG232
mng-umap@100
——0.608

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ESTROGEN_RESPONSE_EARLY0.330Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.320Inavolisib— uncovered
HYPOXIA0.310Idelalisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
APOPTOSIS0.180Idelalisib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
P53_PATHWAY0.170Idelalisib— uncovered
ADIPOGENESIS0.160Inavolisib— uncovered
APICAL_SURFACE0.160Temsirolimus— uncovered
NOTCH_SIGNALING0.160Inavolisib— uncovered
HEME_METABOLISM0.150Temsirolimus— uncovered
UV_RESPONSE_DN0.150Inavolisib— uncovered
GLYCOLYSIS0.110Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.110Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
ANDROGEN_RESPONSE0.090Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.070Idelalisib— uncovered
MYOGENESIS0.070Inavolisib— uncovered